Acute Megakaryoblastic Leukemia

This is a type of leukemia, which is cancer of the blood cells. It's a specific kind called acute megakaryoblastic leukemia. It happens when the bone marrow, where blood cells are made, produces too many immature megakaryocyte cells. These cells are a type of large cell found in the bone marrow. The leukemia affects a certain percentage of the blood cells, usually 20 to 30 percent. Sometimes, the bone marrow becomes very fibrous, which is called myelofibrosis. This condition can cause symptoms like fatigue, fever, and easy bruising or bleeding.

Condition

What people with Acute Megakaryoblastic Leukemia report

Every report comes from a Lived member, sent anonymously.

Have you had Chemotherapy infusion for Acute Megakaryoblastic Leukemia?

NameHow it went

About Acute Megakaryoblastic Leukemia

What It Is

Acute megakaryoblastic leukemia (AMKL) is a rare type of acute myeloid leukemia (AML), a fast-growing cancer of the blood-forming cells in the bone marrow. In AMKL, the leukemia cells are megakaryoblasts: very immature forms of megakaryocytes, the large marrow cells that normally make platelets. These abnormal cells multiply without maturing and crowd out normal blood production. That is what causes the main symptoms: too few red cells (tiredness, paleness), too few platelets (easy bruising, bleeding and tiny red spots on the skin called petechiae) and too few working white cells (frequent or stubborn infections and fevers). Doctors may also call it AML M7, a label from an older classification system. AMKL occurs mainly in young children and makes up roughly 4 to 15 percent of childhood AML. It is much less common in adults. The disease behaves very differently in three groups (children with Down syndrome, other children, and adults), so treatment and outlook are almost always discussed group by group.

Causes & Risk Factors

AMKL begins when blood-forming cells acquire genetic changes that make them multiply without maturing. In most people the reason those changes happen is unknown, and nothing a person or parent did is known to cause it. Down syndrome is the strongest known risk factor. Children with Down syndrome are about 500 times more likely than other children to develop AMKL, almost always before age 4. Their leukemia cells carry a change in a gene called GATA1 alongside the extra chromosome 21. Many of these children first have transient abnormal myelopoiesis (TAM), a newborn condition in which leukemia-like cells appear in the blood. TAM affects about 1 in 10 newborns with Down syndrome and usually clears on its own within the first 3 months, but about 10 to 30 percent of babies who had it later develop myeloid leukemia of Down syndrome (the name for AMKL in these children), on average at around 16 months of age. The same pattern can occur in a child who has the extra chromosome 21 in only some cells (mosaicism) and none of the usual features of Down syndrome. In children without Down syndrome, AMKL is usually driven by a fusion gene, formed when pieces of two chromosomes break and join. In adults, AMKL often develops after an earlier bone marrow disorder such as myelodysplastic syndrome (a condition in which the marrow makes faulty blood cells), or after chemotherapy for a different cancer.

How It's Diagnosed

Suspicion usually starts with a complete blood count (CBC) showing low platelets, low red cells or abnormal immature cells, often in a young child who is pale, bruising easily or unusually tired. The diagnosis is confirmed with bone marrow tests: an aspiration, which draws liquid marrow through a needle, and a biopsy, which removes a small core of bone and marrow, usually from the hip. AMKL can be harder to pin down than other leukemias. Scarring of the marrow (myelofibrosis) is common and can make samples harder to obtain and interpret, and the leukemia sometimes forms a solid mass outside the marrow that can be mistaken for a different tumor. Specialists confirm that the cells belong to the platelet-making line with flow cytometry (a lab test that reads proteins on the surface of individual cells) or tissue stains that detect markers found on platelet-lineage cells. Genetic testing of the leukemia cells is central, not optional. It looks for a GATA1 change and an extra chromosome 21 (which may be present only in the leukemia cells), and for fusion genes such as CBFA2T3::GLIS2 or RBM15::MRTFA. These results place the person in a risk group and largely decide which treatment plan fits. In a newborn with leukemia-like blood findings, doctors try to wait for genetic results before starting chemotherapy when it is safe to do so, because TAM often resolves without it.

Treatment Options

AMKL is treated by a leukemia team, ideally at a center with experience in this rare disease, and how intense the treatment is depends heavily on which group a person falls into. Children with Down syndrome who are 4 or younger at diagnosis usually need less treatment than other children with AML. Their leukemia cells are unusually sensitive to cytarabine, a chemotherapy drug that is a mainstay of AML treatment, while the children themselves are more vulnerable to infections and heart effects from chemotherapy. They therefore receive a deliberately less intensive chemotherapy plan, and a stem cell transplant is not recommended in first remission. Children with Down syndrome who are older than 4 more often have a leukemia that behaves like AML in other children and usually need standard intensive treatment unless testing finds a GATA1 change. TAM in a newborn usually needs only close watching; a baby with severe TAM may be given cytarabine to ease symptoms, although this has not been shown to prevent leukemia later. Children without Down syndrome receive intensive AML chemotherapy in cycles over several months: an induction phase to bring the leukemia into remission (no detectable leukemia in the marrow), then further cycles to keep it from returning. Many are offered an allogeneic stem cell transplant, using blood-forming cells from a matched donor, while in first remission, especially when the genetic results point to high risk. A transplant can control leukemia that chemotherapy alone may not, but it carries substantial risks of its own. A transplant tends to work best while the leukemia is in remission, so it is usually planned for first remission rather than held back until a relapse. Even so, one large trial group found no clear survival gain from transplanting children in first remission, so specialists still disagree about which children gain most, and the genetic subtype weighs heavily in that decision. In adults, AMKL often responds poorly to chemotherapy and tends to return, so a donor stem cell transplant is generally considered the main route to lasting control for those well enough to have one. At any age, a clinical trial is worth asking about, because standard treatment works poorly for several AMKL subtypes.

What to Expect

Outlook varies more with the type of AMKL than with almost anything else. Children with Down syndrome who are diagnosed at 4 or younger have one of the best outlooks in childhood leukemia: in large trials, close to 9 in 10 were alive and free of leukemia years later. For other children, AMKL has historically had worse results than most childhood AML, with roughly half to 7 in 10 surviving five years in recent European trials. That average hides a wide range. Children whose leukemia carries the RBM15::MRTFA fusion (mostly infants) or a GATA1 change without Down syndrome have done comparatively well in some studies, while the CBFA2T3::GLIS2 fusion marks a very high-risk form that often resists treatment. In adults, AMKL is one of the harder forms of AML to treat: fewer people reach remission and survival is usually shorter than with other AML types. Treatment is demanding. Intensive AML chemotherapy causes long stretches of very low blood counts, when transfusions, infection prevention and hospital-level supportive care are needed, so families should plan for long periods in or near the treatment center. After treatment, regular blood counts check for relapse; in childhood AML about half or more of relapses happen within the first year, and most within 4 years. Children who received anthracycline chemotherapy (a drug group that can affect the heart) need long-term checks of heart function, and survivors are followed for other late effects of treatment. For a baby with Down syndrome who had TAM, the chance of leukemia continues after TAM clears, so the follow-up plan the care team sets through early childhood matters.

When to Seek Help

See a doctor promptly, within a day or two, if a child or adult has unexplained bruising, tiny red or purple spots on the skin, growing paleness and tiredness, or repeated fevers. These signs have many causes, but a blood count can quickly show whether the bone marrow is involved. Get seen the same day for a fever together with new spots or bruising, a child who seems very unwell, or bleeding that does not stop with pressure. This is especially worth doing for a young child with Down syndrome, including one whose newborn TAM has already cleared. During treatment, call the care team right away for a temperature of 100.5 F (38 C) or higher, or chills, because infections when white cells are low can become life threatening quickly. Check with the team before giving fever-reducing medicine, since it can hide a fever. Also call right away for bleeding that does not stop after a few minutes of pressure, black or bloody stools, red or pink urine, or a bad headache, vision change, confusion or unusual sleepiness, which can signal bleeding in the brain when platelets are low.

Questions to Ask Your Doctor

  1. 1.What did the genetic tests on the leukemia cells show, and which risk group does that put us in?
  2. 2.For a baby with Down syndrome: is this TAM that may clear on its own, or leukemia that needs treatment now, and how will we follow it?
  3. 3.Is a stem cell transplant recommended in first remission for this type of AMKL, and what are the reasons for and against?
  4. 4.Is there a clinical trial that fits this subtype, and where is it offered?
  5. 5.During treatment, which symptoms mean we should call right away, and how do we reach the team after hours?

Last reviewed • Oct 2026

Educational content, not medical advice.